Levetiracetam Krka (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This interaction stabilises neuronal membranes and diminishes abnormal electrical activity, thereby lowering the likelihood of seizure initiation and spread.

The dosage of Levetiracetam Krka is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals determine the appropriate dose and titration schedule for each patient.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk, but there are limited human data. It may be used during pregnancy only if the potential benefit justifies the potential risk. Breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancing agents such as valproate. It generally has a favourable interaction profile and is well tolerated, but individual response and side‑effect patterns vary, so clinicians choose therapy based on patient‑specific factors.

Levetiracetam Krka should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Levetiracetam Krka is taken orally, usually as a tablet, with or without food. The exact administration schedule—once daily, twice daily, or more frequent—depends on the prescriber’s dosing plan and the patient’s therapeutic needs.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, significant mood or behavioural changes (including depression or suicidal thoughts), and hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored closely for these events and seek immediate medical attention if they occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for pregnant or breastfeeding women unless the benefits outweigh potential risks.